Alerta De Seguridad para ARCHITECT Active-B12 Reagent Kit

Según Department of Health, este evento ( alerta de seguridad ) involucró a un dispositivo médico en Hong Kong que fue producido por Abbott.

¿Qué es esto?

Las alertas proporcionan información importante y recomendaciones sobre los productos. Aunque se haya emitido una alerta, esto no significa necesariamente que el producto se considera peligroso. Las alertas de seguridad, dirigidas a trabajadores de la salud y a usuarios, pueden incluir retiro de equipos. Pueden ser escritas por los fabricantes, pero también por funcionarios del área de salud.

Más información acerca de la data acá
  • Tipo de evento
    Safety alert
  • Fecha
    2016-12-02
  • Fecha de publicación del evento
    2016-12-02
  • País del evento
  • Fuente del evento
    DH
  • URL de la fuente del evento
  • Notas / Alertas
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • Notas adicionales en la data
    Medical Device Safety Alert
  • Causa
    Medical device safety alert: abbott architect active-b12 reagent kit medical device manufacturer, abbott, has issued a medical device safety alert concerning its architect active-b12 reagent kit. the affected devices are identified as follows:- list number: (i) 3p24-25, (ii) 3p24-35 lot number: (i)10533up00, (ii)10534up00 udi number: (i) [(01) 00380740006365, (17) 170529, (10) 10533up00, (240) 3p2425] (ii) [(01) 00380740006372, (17) 170529, (10) 10534up00, (240) 3p2435] expiration date: 29 may 2017 the manufacturer has identified a lot specific stability issue with both reagent lots 10533up00 and 10534up00. as the reagent ages, relative light unit (rlu) values for the calibration curve will decrease causing patient results calculated from this depressed curve to over-recover, potentially resulting in falsely elevated patient results. controls may not reflect reagent instability as recalibration may result in control values within acceptable ranges. there is a potential for falsely elevated active-b12 results to be generated when using architect active-b12 reagent lots 10533up00 and 10534up00. internal studies have determined the worst case magnitude of elevation to be up to 30% for active-b12 concentrations close to 20 pmol/l and up to 20% for concentrations close to 30 pmol/l. affected users are instructed to discontinue use and immediately destroy any remaining inventory of architect active-b12 reagent lots 10533up00 and 10534up00 and order replacement material. they should also review the information with their medical director to determine if a review of results previously generated with reagent lots 10533up00 and 10534up00 is required. according to the local supplier, the affected products are distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 2 december 2016.

Device

  • Modelo / Serial
  • Descripción del producto
    Medical Device Safety Alert: Abbott ARCHITECT Active-B12 Reagent Kit
  • Manufacturer

Manufacturer

  • Empresa matriz del fabricante (2017)
  • Comentario del fabricante
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    DH